Page last updated: 2024-08-24

triazoles and Mesothelioma

triazoles has been researched along with Mesothelioma in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Colangelo, D; Osella, D; Zanellato, I1
Alessandrini, G; Amoreo, CA; Blandino, G; Ciliberto, G; Cioce, M; De Maria, R; di Martino, S; Facciolo, F; Galati, R; Nuvoli, B; Pass, HI; Strano, S1
Chew, SH; Misawa, N; Nagai, H; Okazaki, Y; Toyokuni, S; Yasui, H1
Toyokuni, S1
Cominetti, D; De Cesare, M; Deraco, M; Doldi, V; Friedlander, S; Gandellini, P; Kauffman, MG; Landesman, Y; Lopergolo, A; Pennati, M; Shacham, S; Zaffaroni, N1

Reviews

1 review(s) available for triazoles and Mesothelioma

ArticleYear
Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.
    Redox report : communications in free radical research, 2014, Volume: 19, Issue:1

    Topics: Adsorption; Animals; Asbestos; Asbestosis; Benzoates; Carcinogens, Environmental; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Deferasirox; Ferric Compounds; Ferric Oxide, Saccharated; Genes, p16; Glucaric Acid; Humans; Iron Chelating Agents; Iron Overload; Japan; Kidney Neoplasms; Male; Mesothelioma; Mineral Fibers; Peritoneal Neoplasms; Phlebotomy; Pleural Neoplasms; Rats; Triazoles

2014

Other Studies

4 other study(ies) available for triazoles and Mesothelioma

ArticleYear
JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
    Current cancer drug targets, 2018, Volume: 18, Issue:8

    Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Azepines; beta-Galactosidase; Cell Cycle Checkpoints; Cell Cycle Proteins; Cellular Senescence; Cisplatin; DNA Breaks; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Nuclear Proteins; Pleural Neoplasms; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-myc; Transcription Factors; Transcription, Genetic; Triazoles

2018
HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.
    Oncogene, 2018, Volume: 37, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cellular Senescence; Cisplatin; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred NOD; Mice, SCID; Pemetrexed; Secretory Pathway; Triazoles

2018
Deferasirox induces mesenchymal-epithelial transition in crocidolite-induced mesothelial carcinogenesis in rats.
    Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:11

    Topics: Animals; Asbestos, Crocidolite; Benzoates; Cell Transformation, Neoplastic; Deferasirox; Epithelial-Mesenchymal Transition; Female; Iron; Iron Chelating Agents; Male; Mesothelioma; Phlebotomy; Rats; Spleen; Triazoles

2013
Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    Oncotarget, 2015, May-30, Volume: 6, Issue:15

    Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Exportin 1 Protein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazines; Inhibitor of Apoptosis Proteins; Karyopherins; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, SCID; Neoplasm Proteins; Oxadiazoles; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Survivin; Thiazoles; Triazoles; Tumor Suppressor Protein p53

2015